4//SEC Filing
HAMED KAMAL 4
Accession 0000950170-23-027860
CIK 0001701108other
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 8:30 AM ET
Size
5.4 KB
Accession
0000950170-23-027860
Insider Transaction Report
Form 4
HAMED KAMAL
Chief Medical Officer
Transactions
- Award
Common Stock
2023-06-12+140,000→ 615,957 total
Footnotes (2)
- [F1]On August 4, 2022, the Reporting Person was granted a target of 140,000 performance-based restricted stock units ("RSUs") under the Issuer's 2019 Inducement Equity Incentive Plan, as amended. Each RSU represents the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On June 12, 2023, the Board of Directors of the Issuer determined that 100% of the performance-based conditions were met resulting in 140,000 RSUs earned by the Reporting Person. The RSUs vest in two equal annual installments on September 12, 2023 and September 12, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]Consists of RSUs held by the Reporting Person.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
Related Parties
1- filerCIK 0001946366
Filing Metadata
- Form type
- 4
- Filed
- Jun 13, 8:00 PM ET
- Accepted
- Jun 14, 8:30 AM ET
- Size
- 5.4 KB